Literature DB >> 6701455

Conventional malabsorption tests: do they detect the adult patient with villous atrophy?

R Gillberg, G Dotevall, W Kastrup, G Lindstedt, H Mobacken, B Swolin.   

Abstract

A total number of 134 patients with subtotal or partial villous atrophy, of whom 49 had dermatitis herpetiformis, were investigated with blood folate assay and xylose and lactose absorption tests. Faecal fat excretion was determined in 71 patients without dermatitis herpetiformis (coeliac group). A comparison was made between three patient groups, the patients with dermatitis herpetiformis and the coeliac patients studied in 1970-74 and 1975-79, respectively. From clinical and biochemical analyses of these patients we conclude that although a combination of the four malabsorption tests used here still detect a majority of coeliac patients, small intestinal biopsy may reveal villous atrophy also in patients without any laboratory evidence for malabsorption by these commonly used tests. In dermatitis herpetiformis, however, the sensitivity of the tests used was low; these malabsorption tests therefore have little diagnostic value in this category of patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6701455     DOI: 10.3109/00365518409083792

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

1.  Hydrogen breath test with D-xylose for celiac disease screening is as useful in the elderly as in other age groups.

Authors:  F Casellas; J Sardi; I de Torres; J R Malagelada
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

2.  Improved screening for intestinal villous atrophy by D-xylose breath test.

Authors:  F Casellas; I de Torres; J R Malagelada
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

3.  Clinical applicability of shortened D-xylose breath test for diagnosis of intestinal malabsorption.

Authors:  F Casellas; J R Malagelada
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.